StreetInsider.com News Articles

Form F-6EF Zealand Pharma A/S/ADR Filed by: Citibank,N.A./ADR

Wed, 14 May 2025 17:08:00 -0400

si-local-file:///var/storage/secattach/20250514/24798916.html

Form F-6EF Zealand Pharma A/S/ADR Filed by: Citibank,N.A./ADR

Wed, 14 May 2025 17:08:00 -0400

si-local-file:///var/storage/secattach/20250514/24798916.html

Form F-6EF Zealand Pharma A/S/ADR Filed by: Citibank,N.A./ADR

Wed, 14 May 2025 17:08:00 -0400

si-local-file:///var/storage/secattach/20250514/24798916.html

Jefferies Reiterates Buy Rating on Zealand Pharma A/S (ZEAL:DC) (ZLDPF)

Wed, 11 Sep 2024 05:35:15 -0400

Jefferies analyst Lucy Codrington reiterated a Buy rating and DKK1,100.00 price target on Zealand Pharma A/S (ZEAL:DC) (OTC: ZLDPF).

Jefferies Reiterates Buy Rating on Zealand Pharma A/S (ZEAL:DC) (ZLDPF)

Wed, 11 Sep 2024 05:35:15 -0400

Jefferies analyst Lucy Codrington reiterated a Buy rating and DKK1,100.00 price target on Zealand Pharma A/S (ZEAL:DC) (OTC: ZLDPF).

Zealand Pharma A/S (ZEAL:DC) (ZLDPF) PT Raised to DKK1,100 at BTIG, 'We view the data as an encouraging'

Mon, 09 Sep 2024 16:01:25 -0400

BTIG analyst Julian Harrison raised the price target on Zealand Pharma A/S (ZEAL:DC) (OCT: ZLDPF) to DKK1,100.00 (from DKK1,050.00) while maintaining a Buy rating.

The analyst comments "We view the data as an encouraging early result for a differentiated mechanism (GLP1/GLP2 agonist) within the broader incretin category. Patients treated with dapiglutide over 13wks achieved a mean weight loss of up to 6.2% and placebo recipients experienced mean weight gain of 2.1%. This placebocorrected result of -8.3% compares favorably to 15mg tirzepatide at 13wk (-7.2%) in SURMOUNT-1 (Exhibit 1). Furthermore, we noted a significant gender-skew in the enrolled patients (n=54) which reflected

Zealand Pharma A/S (ZEAL:DC) (ZLDPF) PT Raised to DKK1,100 at BTIG, 'We view the data as an encouraging'

Mon, 09 Sep 2024 16:01:25 -0400

BTIG analyst Julian Harrison raised the price target on Zealand Pharma A/S (ZEAL:DC) (OCT: ZLDPF) to DKK1,100.00 (from DKK1,050.00) while maintaining a Buy rating.

Zealand Pharma A/S (ZEAL:DC) (ZLDPF) PT Raised to DKK1,100 at BTIG, 'We view the data as an encouraging'

Mon, 09 Sep 2024 16:01:25 -0400

BTIG analyst Julian Harrison raised the price target on Zealand Pharma A/S (ZEAL:DC) (OCT: ZLDPF) to DKK1,100.00 (from DKK1,050.00) while maintaining a Buy rating.

Selloff in this European pharma stock 'unwarranted' says Jefferies

Thu, 18 Jul 2024 22:30:00 -0400

Jefferies analysts have called Wednesday’s selloff in Zealand Pharma (OTC: ZLDPF) shares as "unwarranted”, with its analysts arguing that the selloff should not impact other GLP-1 players, particularly those focused on oral treatments.

The New York-headquartered financial services company reiterated its "Buy" rating on the stock, with a price target of DKK 1,100.00, an 18% upside from its current trading price of DKK 934.50.

Danish biotechnology company Zealand Pharma specializes in the development of novel peptide drugs targeting rare and metabolic diseases, as well as gastrointestinal and cardiovascular disorders, including amylin.

Jefferies has maintained that the potential for amylin-based therapies remains intact on

Selloff in this European pharma stock 'unwarranted' says Jefferies

Thu, 18 Jul 2024 22:30:00 -0400

The New York-headquartered financial services company reiterated its "Buy" rating on the stock, with a price target of DKK 1,100.00, an 18% upside from its current trading price of DKK 934.50.

Jefferies has maintained that the potential for amylin-based therapies remains intact on

Zealand Pharma stock soars 35% on strong trial results for its weight loss treatment

Mon, 26 Feb 2024 15:12:17 -0400

Danish biotechnology research company Zealand Pharma (OTC: ZLDPF) saw its shares soar more than 35% in Copenhagen on Monday after following positive results from a trial of its liver disease treatment, signaling potential competition in the thriving weight loss drug sector.

The stock ended the session at a new closing high of DKK648.50.

In the Phase 2 trial of the survodutide drug, 83% of adults exhibited positive outcomes for a type of liver inflammation associated with excess fat cells, known as "MASH," the company disclosed.